Tumor necrosis factor (TNFalpha) is a main mediator in the inflammatory answer of many diseases. The anti-TNFalpha antibodies (infliximab, etanercept, adalimumab) block their action, preventing the inflammatory answer and the damage it produces. In this paper, we review the treatment of some diseases in which these drugs are experimentally used. These are: ulcerative colitis, sarcoidosis, graft-versus-host disease, adult Still's disease, some systemic vasculitis, systemic lupus erythematosus and Behçet disease.